Back HCV Disease Progression Transplant/Artificial Liver

Liver Transplant - HCV

AASLD 2014: HIV Positive People Have High Survival Rates After Liver Transplants Due to HCC

People with HIV -- most of whom were coinfected with hepatitis B or C -- generally had good outcomes after liver transplantation due to hepatocellular carcinoma (HCC), with 5-year survival rates similar to those of HIV negative transplant recipients and better than those of people who underwent other types of liver cancer treatment, researchers reported at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting this week in Boston.

alt

Read more:

Increased Distance Reduces Likelihood of Liver Transplant

alt

Living and receiving health care further away from a transplant center was associated with lower chances of being wait-listed for or receiving a liver transplant, according to a study of U.S. veterans described in the March 26 edition of JAMA.

Read more:

AASLD 2013: Hepatitis C Treatment Reduces Liver Cancer and Death, But Most Remain Untreated

Hepatitis C treatment that leads to viral suppression significantly reduces the likelihood of liver disease progression and liver-related mortality, but most patients remain untreated, according to a presentation at the 64th AASLD Liver Meeting last week in Washington, DC. Other studies found that a growing proportion of liver transplants are due to hepatocellular carcinoma, which can still occur even after treatment.

alt

Read more:

AASLD 2013: Aspirin and Cenicriviroc May Help Reduce Liver Fibrosis

Hepatitis C patients who took low-dose aspirin after liver transplantation experienced slower fibrosis progression, researchers reported at the AASLD Liver Meeting this month in Washington, DC. Two other studies showed that cenicriviroc -- a drug being developed for HIV treatment that blocks both CCR5 and CCR2 cell surface receptors -- had anti-inflammatory and anti-fibrotic activity in mice and rats.

alt

Read more:

AASLD 2013: Simeprevir with Pegylated Interferon/ Ribavirin Cures Genotype 1 Hepatitis C in 80%

Simeprevir added to pegylated interferon and ribavirin performed well in difficult-to-treat treatment-naive patients and prior relapsers with genotype 1 chronic hepatitis C, according to 2 poster presentations at the 64th AASLD Liver Meeting last week in Washington, DC, as described in an announcement by Janssen.

alt

Read more: